Skip to content

Editors

Harry Cassin
Publisher and Editor

Andy Spalding
Senior Editor

Jessica Tillipman
Senior Editor

Bill Steinman
Senior Editor

Richard L. Cassin
Editor at Large

Elizabeth K. Spahn
Editor Emeritus

Cody Worthington
Contributing Editor

Julie DiMauro
Contributing Editor

Thomas Fox
Contributing Editor

Marc Alain Bohn
Contributing Editor

Bill Waite
Contributing Editor

Russell A. Stamets
Contributing Editor

Richard Bistrong
Contributing Editor

Eric Carlson
Contributing Editor

Posts Tagged: GlaxoSmithKline

Peter Humphrey and wife released from prison

British investigator Peter Humphrey and his American wife Yu Yingzeng have been released early from prison in China.
 
Humphrey and Yu were jailed in August last year for illegally obtaining and selling personal information of Chinese citizens.… Continue Reading

Pharma news: China restricts hospital drug sales

China is pushing reforms at public hospitals in the wake of widespread complaints about inadequate healthcare services and corruption related to drug sales.

According to a guideline issued by the State Council, reforms that were piloted in 17 cities in 2010 will be expanded to the country’s 6,800 public hospitals by 2017.… Continue Reading

China state newspaper accuses foreign firms of tax evasion

China’s state-run newspaper People’s Daily has accused multinational companies of avoiding taxes in China and urged authorities to take measures to combat tax evasion.
 
Foreign companies have been diverting their profits to overseas branches or their parent companies in order to avoid paying taxes in China, People’s Daily said.… Continue Reading

Novartis employee pleads guilty in Poland bribe case

An executive at Swiss pharma Novartis pleaded guilty in a bribery prosecution in Poland, the company has confirmed.

Poland’s anti-corruption bureau charged two women with bribery. Prosecutors said they gave a health fund official a tourist trip worth more than $1,000 in exchange for backing the sale of a particular drug, Reuters said.… Continue Reading

With GSK, China flipped the compliance switch

GlaxoSmithKline PLC (GSK) may well be a watershed in the global fight against bribery and corruption. Behavior and conduct, which was illegal under Chinese law but previously tolerated and even accepted by Chinese government officials, quickly became a quagmire that the company was caught in when charges of corruption were leveled against them last year.… Continue Reading